LABB Stock Chart & Stats
$14.45
$0.08(0.55%)
At close: 4:00 PM EDT
$14.45
$0.08(0.55%)
Day’s Range― - ―
52-Week Range$13.85 - $23.60
Previous CloseN/A
Volume2.80M
Average Volume (3M)3.52M
Market Cap
$14.68B
Enterprise Value$20.09K
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$7.85B
Price to Earnings (P/E)8.9
Beta0.85
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.45%
Share Statistics
EPS (TTM)1.65
Shares Outstanding1,000,000,000
10 Day Avg. Volume3,244,141
30 Day Avg. Volume3,515,042
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)1.57
Price to Sales (P/S)0.99
P/FCF Ratio8.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.00Price Target Upside10.73% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.05
Revenue Forecast (FY)$17.99B
Genomma Lab Internacional SAB de CV News
LABB FAQ
What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?
Genomma Lab Internacional SAB de CV Class B lowest stock price was $13.85 and its highest was $23.60 in the past 12 months.
What is Genomma Lab Internacional SAB de CV Class B’s market cap?
Genomma Lab Internacional SAB de CV Class B’s market cap is $14.68B.
When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?
Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Oct 28, 2026 which is in 86 days.
How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?
Genomma Lab Internacional SAB de CV Class B released its earnings results on Jul 23, 2026. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.47 by -$0.1.
Is Genomma Lab Internacional SAB de CV Class B overvalued?
According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Undervalued.
Does Genomma Lab Internacional SAB de CV Class B pay dividends?
Genomma Lab Internacional SAB de CV Class B pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 5.45%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here
What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?
Genomma Lab Internacional SAB de CV Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?
Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.
What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?
Genomma Lab Internacional SAB de CV Class B reported an EPS of $0.37 in its last earnings report, missing expectations of $0.47. Following the earnings report the stock price went down -3.168%.
Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?
Currently, no hedge funds are holding shares in MX:LABB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genomma Lab Internacional SAB de CV Class B
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
LABB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: management reported clear signs of recovery in Mexico (improving monitored sellout, narrowing sell-in/sell-out gap, and strong Suerox momentum), structural productivity gains that expanded gross margin, solid regional growth in Latin America, and a conservative balance sheet with liquidity improvements. At the same time, meaningful top-line pressures remain (net sales down 6% and a strong peso translation headwind), the United States market is disrupted, EBITDA margin contracted on operational deleverage, and free cash flow was materially lower due to working capital investments. Overall, management framed the negatives as temporary and deliberate investments to defend and grow market share while expecting gradual recovery in H2 2026 and margin normalization in 2027.View all MX:LABB earnings summariesLABB Stock 12 Month Forecast
Average Price Target
$16.00
▲(10.73% Upside)